Consensus Axonics, Inc.

Equities

AXNX

US05465P1012

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-24 pm EDT			5-day change	1st Jan Change
66.64 ^USD	+0.26%		-0.83%	+7.09%

Apr. 04	Boston Scientific, Axonics Receive FTC Second Request on Merger Deal	MT
Apr. 04	Boston Scientific, Axonics Merger Prompts FTC to Request Additional Information	DJ

Evolution of the average Target Price on Axonics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

174d910b008423b.rjxT9zNipt5_ldG5ldjedGrfS3d5X73DM7Vrd3z5wy4.7W4cvksW6rgHwuLf2K6QNSSROk8BBtSgQIYZP0W77hjqfyGhYCPf6CCg4Q~056e573c636ece21c14e55efb56fc674

Analyst Recommendations on Axonics, Inc.

Needham Downgrades Axonics to Hold From Buy	Jan. 17	MT
Truist Securities Downgrades Axonics to Hold From Buy, Adjusts Price Target to $71 From $73	Jan. 12	MT
CL King Downgrades Axonics to Neutral From Buy	Jan. 12	MT
Leerink Partners Downgrades Axonics to Market Perform From Outperform, Sets Price Target at $71	Jan. 12	MT
Piper Sandler Downgrades Axonics to Neutral From Overweight, Cuts Price Target to $71 From $75	Jan. 12	MT
Wells Fargo Downgrades Axonics to Equalweight From Overweight, Raises Price Target to $71 From $68	Jan. 10	MT
Nephron Research Downgrades Axonics to Hold From Buy, Raises Price Target to $71 From $65	Jan. 09	MT
Wolfe Research Downgrades Axonics to Peer Perform From Outperform	Jan. 09	MT
RBC Lifts Price Target on Boston Scientific to $67 From $61, Cites Stock Runup, Growth Opportunities Amid Axonics Deal, Outperform Kept	Jan. 09	MT
RBC Downgrades Axonics to Sector Perform From Outperform, Raises Price Target to $71 From $69 Amid Boston Scientific Deal	Jan. 09	MT
Investors lower their expectations	Jan. 08
Needham Adjusts Price Target on Axonics to $63 From $76, Maintains Buy Rating	23-10-31	MT
Morgan Stanley Cuts Price Target on Axonics to $69 From $76, Keeps Overweight Rating	23-10-31	MT
Baird Adjusts Price Target on Axonics to $70 From $69, Maintains Outperform Rating	23-07-28	MT
Needham Adjusts Price Target on Axonics to $76 From $73, Maintains Buy Rating	23-07-28	MT
KeyBanc Initiates Axonics at Overweight With $70 Price Target, Confident in Ability to Meet or Exceed Consensus Growth Views	23-07-13	MT
RBC Cuts Price Target on Axonics to $75 From $85, Maintains Outperform Rating	23-07-12	MT
CL King Starts Axonics at Buy With $75 Price Target	23-05-23	MT
Needham Adjusts Price Target on Axonics to $73 From $71, Maintains Buy Rating	23-05-02	MT
Truist Securities Adjusts Price Target on Axonics to $73 From $82, Maintains Buy Rating	23-04-17	MT
Mizuho Initiates Axonics at Buy With $75 Price Target	23-04-14	MT
Needham Upgrades Axonics to Buy From Hold, Price Target is $71	23-03-24	MT
Morgan Stanley Adjusts Price Target on Axonics to $76 From $92, Maintains Overweight Rating	23-01-06	MT
Truist Securities Adjusts Price Target on Axonics to $82 From $90, Maintains Buy Rating	22-12-20	MT
Truist Securities Adjusts Price Target on Axonics to $90 From $80, Maintains Buy Rating	22-11-01	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

66.64 USD

Average target price

71.8 USD

Spread / Average Target

+7.74%

High Price Target

75 USD

Spread / Highest target

+12.55%

Low Price Target

71 USD

Spread / Lowest Target

+6.54%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Axonics, Inc.

Needham & Co.
Truist Securities
Leerink Partners
CL King
Piper Sandler
Wells Fargo Securities
Nephron Research
Wolfe Research
RBC Capital Markets
Morgan Stanley
Baird
KeyBanc Capital Markets
Mizuho Securities
Jefferies & Co.
BofA Securities
SVB Leerink
Barclays

Ratings for Axonics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar